Systems and methods for treating patients with processed lipoaspirate cells

• US 20050074436A1
• Filed: 07/07/2003
• Published: 04/07/2005
• Est. Priority Date: 12/07/2001
• Status: Active Grant

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Cytori Therapeutics Incorporated
• Inventors: Fraser, John K., Hedrick, Marc H.
• Granted Patent: US 7,429,488 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61B 10/0283 with vacuum aspiration, e.g. caused by retractable plunger or by connected syringe A61B10/025, A61B10/0266 take precedence
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/35 Fat tissue; Adipocytes; Stromal cells; Connective tissues adipose-derived stem cells A61K35/28; collagen A61K38/39
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61M 1/76 Handpieces specially for suction-irrigation A61M1/774, aspiration tips A61M1/84
• CPC Class Codes: A61M 2202/08 Lipoids
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12M 47/04 : Cell isolation or sorting purging biological preparations of unwanted cells C12N5/0081, determining the presence or kind of microorganism C12Q1/04
• CPC Class Codes: C12N 2506/1384 : from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 : Vascular Endothelial cells

Abstract

Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.

Claims

1-92. -92. (canceled)

93. A method of treating a patient, comprising:

(a) providing a tissue removal system;

(b) removing adipose tissue from a patient using the tissue removal system, the adipose tissue having a concentration of stem cells;

(c) processing at least a part of the adipose tissue to obtain a concentration of stem cells other than the concentration of stem cells of the adipose tissue before processing, wherein the adipose tissue is degraded without substantially damaging cells contained within the tissue by mixing the adipose tissue with at least one enzyme that disrupts intercellular contact for a short amount of time relative to an amount of time that the enzyme would otherwise be left on the adipose tissue to fully disaggregate the tissue; and

(d) administering the stem cells to a patient without removing the stem cells from the tissue removal system before being administered to the patient.

94. The method as set forth in claim 93, wherein (d) includes combining the concentration of stem cells with another part of the adipose tissue and administering the combination to the patient.

95. The method as set forth in claim 94, wherein a volume of the at least a part of the adipose tissue differs by more than 25% from a volume of the other part of the adipose tissue.

96. The method as set forth in claim 94, wherein a volume of the at least a part of the adipose tissue differs by more than 100% from a volume of the other part of the adipose tissue.

97. The method as set forth in claim 93, wherein (c) is followed by mixing the concentration of stem cells from the at least a part of adipose tissue with another part of the adipose tissue, and wherein (d) comprises administering the mixture to a patient.

98. The method as set forth in claim 97, wherein a volume of the at least a part of the adipose tissue differs by more than 50% from a volume of the other part of the adipose tissue.

99. The method as set forth in claim 97, wherein a volume of the at least a part of the adipose tissue differs by more than 150% from a volume of the other part of the adipose tissue.

100. The method as set forth in claim 93, wherein (c) comprises only partially disaggregating the at least a portion of the adipose tissue.

101. The method as set forth in claim 93, wherein (c) comprises processing the adipose tissue into multiple portions of adipose tissue.

102. The method as set forth in claim 101, wherein (c) comprises only partially disaggregating at least one of the multiple portions of adipose tissue.

103. The method as set forth in claim 101, further comprising mixing at least two of the portions of adipose tissue together.

104. The method as set forth in claim 102, wherein at least one of the portions of adipose tissue has been processed to form a pellet containing stem cells.

105. A method of treating a patient, comprising:

(a) providing an adipose tissue removal system;

(b) removing adipose tissue from a patient using the adipose tissue removal system, the adipose tissue having a concentration of stem cells; and

(c) processing the adipose tissue to increase the concentration of stem cells in the adipose tissue;

(d) mixing the adipose tissue having the concentrated stem cells with another portion of adipose tissue; and

(e) administering the mixed adipose tissue to a patient.

106. The method as set forth in claim 105, wherein (b) comprises at least one of aspirating adipose tissue from the patient and excising adipose tissue from the patient.

107. The method as set forth in claim 106, wherein (c) further comprises disaggregating the filtered adipose tissue, followed by using a spinning membrane filter.

108. The method as set forth in claim 105, wherein:

(c) comprises separating the adipose tissue into portions, and increasing the concentration of stem cells in at least one portion of adipose tissue; and

(d) comprises mixing the at least one portion of adipose tissue with the other portion of adipose tissue.

109. The method as set forth in claim 108, further comprising only partially disaggregating the at least one portion of adipose tissue.

110. The method as set forth in claim 108, wherein (c) further comprises mixing the at least one portion of adipose tissue with a portion of adipose tissue that does not have an increased concentration of stem cells.

111. The method as set forth in claim 105, wherein the tissue removal system is a closed system, and (c) is performed entirely in the closed system.

112. The method as set forth in claim 105, wherein (b) and (c) are automated.

113. The method as set forth in claim 112, wherein (b), (c), and (d) are automated.

114. The method as set forth in claim 108, wherein a volume of the at least one portion of the adipose tissue differs by more than 25% from a volume of the other portion of the adipose tissue.

115. The method as set forth in claim 108, wherein a volume of the at least one portion of the adipose tissue differs by more than 100% from a volume of the other portion of the adipose tissue.

116. The method as set forth in claim 105, further comprising (f) disposing of parts of the tissue removal system that have contacted body fluids after the mixed adipose has been administered to the patient.